R&D Overview


OP-01 Foam Platform

OP-01 is being developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. Specifically, OP-01 is currently being developed as an improved treatment option for acute otitis externa (“AOE” or “swimmers ear”), a common medical condition of the outer ear canal that affects tens of millions of adults and children each year.

In 2016, we stopped development of the first-generation, antibiotic-only OP-01 product and began development of a second-generation formulation of OP-01. The goal for this second-generation formulation is to produce a clinically differentiated product that rapidly relieves ear pain (an unmet need in AOE), and eradicates infection with less than seven days of treatment. We believe OP-01 will meaningfully improve the standard of care and may become a best-in-class treatment option for AOE.

OP-02 Surfactant Program

OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential first-in-class treatment option for patients with otitis media (“OM”) and Eustachian tube dysfunction (“ETD”). OM and ETD are common medical conditions of the middle ear that affect more than 700 million adults and children each year. OM is a common disorder seen in pediatric practices and is the most frequent reason children are prescribed antibiotics and undergo surgery.